The hallmark of Burkitt lymphoma (BL) is a constitutively activated c-myc gene that drives tumor cell growth. A majority of BL-derived cell lines also carry mutant p53. In addition, the p16INK4a promoter is hypermethylated in most BL biopsies and BL cell lines, leading to silencing of this gene. Activation of c-myc and/or cell cycle dysregulation can induce ARF expression and p53-dependent apoptosis. We therefore investigated the p14ARF-MDM2-p53 pathway in BL cell lines. p14ARF was expressed and localized to nucleoli in all BL carrying mutant p53. Three out of seven BL carrying wt p53 had a homozygous deletion of the CDKN2A locus that encodes both p14ARF and p16INK4a. Three BL carrying wild type p53 retained the CDKN2A locus and overexpressed MDM2. DNA sequencing revealed a point mutation in CDKN2A exon 2 in one of these BL, Seraphine. However, this point mutation did not aect p14ARF's nucleolar localization or ability to induce p53. The Bmi-1 protein that negatively regulates the p14ARF promoter and co-operates with c-myc in tumorigenesis was expressed at low to moderate levels in all BL analysed. Our results indicate that inactivation of the ARF-MDM2-p53 pathway is an essential step during the development of Burkitt lymphoma, presumably as a mechanism to escape c-myc induced apoptosis. Oncogene (2001) 20, 2170 ± 2177.
Introduction
Burkitt lymphoma (BL) is a high grade B-cell lymphoma that regardless of geographical origin carry reciprocal chromosomal translocations that juxtapose the c-myc proto-oncogene on chromosome 8 to the immunglobulin heavy chain locus on chromosome 14 or the kappa or lambda light chain locus on chromosomes 2 or 22 (for a review see Klein, 1993) . In addition, p53 mutations have been found in at least 30% of BL biopsies (Gaidano et al., 1991; Bhatia et al., 1992) and 60-70% of BL cell lines (Wiman et al., 1991; Farrell et al., 1991; Vousden et al., 1993; Cherney et al., 1997) . Mutations in Bcl-6 and Bax and the presence of Epstein-Barr virus (EBV) have also been suggested to contribute to the molecular pathogenesis of BL (Klein, 1993; Gutierrez et al., 1997 Gutierrez et al., , 1999 .
The ARF protein encoded by the CDKN2A locus is a bona ®de tumor suppressor that is frequently lost in various human tumors (reviewed by Sharpless and DePinho, 1999; Sherr and Weber, 2000) . ARF binds and inhibits the p53 antagonist MDM2 that targets p53 for proteasome-mediated degradation through nuclear export (Kamijo et al., 1998; Pomerantz et al., 1998; Tao and Levine, 1999; Zhang and Xiong, 1999; Weber et al., 1999) . Both mouse p19ARF and human p14ARF have been shown to sequester MDM2 in nucleoli and inhibit MDM2's ubiquitin ligase activity, thus triggering p53 accumulation (Honda and Yasuda, 1999; Weber et al., 1999; Weber et al., 2000) . The CDKN2A locus also encodes the tumor suppressor p16INK4a, an inhibitor of the CDK4/cyclin D complex that phosphorylates the pRb protein. Thus, homozygous deletion of CDKN2A will simultaneously disrupt both the pRb and p53 regulatory pathways (see Sherr and Weber, 2000) . Selective inactivation of human p14ARF via deletion of exon 1b has been found in some metastatic melanoma cell lines (Kumar et al., 1998) , and in acute T-cell lymphocytic leukemia (Gardie et al., 1998) . A germline exon 1b deletion has been identi®ed in a rare melanoma-neural system tumor syndrome family (Randerson-Moor et al., 2001) . p14ARF can potentially also be inactivated by overexpression of the Bmi-1 or Twist transcription factors that repress the ARF promoter (Jacobs et al., 1999a; Maestro et al., 1999) . Bmi-1 overexpression has been shown to collaborate with c-myc through averting apoptosis (Jacobs et al., 1999b) . In addition, ARF inactivation may occur through methylation of the ARF promotor (Esteller et al., 2000) .
Mice expressing a c-myc transgene under the control of the immunoglobulin heavy chain enhancer (Em) develop clonal pre-B and B-cell lymphoma, in analogy to human BL (Adams et al., 1985) . A majority of the emerging tumors carry p53 mutation or INK4A/ARF deletion, and/or overexpress MDM2 protein (Eischen et al., 1999) . Loss of INK4A/ARF abrogates B-cell apoptosis in mice carrying an Emmyc transgene, and greatly accelerates lymphomagenesis (Eischen et al., 1999; Schmitt et al., 1999) . These results led us to ask whether the ARF-MDM2-p53 pathway is invariably inactivated in BL, a c-myc driven tumor. We therefore examined the status of p14ARF, MDM2 and Bmi-1 in BL cell lines carrying wild type or mutant p53.
Figure 1 (a) Analysis of p14ARF homozygous deletion by PCR. Homzygous deletion of p14ARF exon 1b and exon 2 was observed in cell lines BL2, BL28 and Ew36 whereas other lines had at least one allele intact. Status of p53 is shown in Table 1 . Exon 1b and exon 2 were always co-deleted and exon1b speci®c deletions were not found. (b) RT-PCR analysis of p14ARF revealed that mRNA is abundantly expressed in BL lines. No signal was detected in BL with homozygous deletion. Materials and methods: BL suspension cells were centrifuged, washed 16 in PBS, resuspended in digestion buer (100 mM NaCl, 10 mM Tris-Cl, 25 mM EDTA, 0.5% w/v SDS, 0.1 mg/ml proteinase K, 20 mg/ml pancreatic RNase) and incubated in a shaker for 12 h at 508C. Samples were extracted using phenol/chloroform/isoamyl alcohol (25 : 24 : 1) and DNA was precipitated using 7.5 M ammonium acetate and 95% EtOH/dH 2 O. Pellets were washed twice in 70% EtOH/dH 2 O and resuspended in Tris-EDTA buer. (2) PCR was carried out using an iCycler TM thermocycler (Bio-Rad laboratories, Hercules, CA, USA). Reactions were performed in a volume of 50 ml containing a minimum of 400 ng DNA template; 10 pmoles of each primer, 10% DMSO, 1.5 mM MgC12, 2.5 mM dNTP's using Taq polymerase and buer provided with the enzyme (GIBCO). Primers used for sequencing of p14ARF were for exon 1b: (F) 5' TGCAGTTAAGGGGGGCAGGAG-3' and (R) 5'-TTATCTCCTCCTCCTCCTAGCCTG-3' and for exon 2: (551R) 5'-TCTGAGCTTTGGAAGCTCT-3' and (42F) 5'-GGAAATTGGAAACTGGAAGC-3'. The PCR products were puri®ed using Qiagen Gelextraction kit (Qiagen) and subsequently sequenced using the same set of primers and the ABI PRISM BigDye Terminator Cycle Sequencing Kit (PE Biosystems, Foster City, CA, USA). Samples were run on an ABI PRISM Sequencer (PE Biosystems). The quality of genomic DNA was con®rmed by parallel PCR ampli®cation of a GAPDH gene exon 8 fragment. p14ARF cDNA was synthesized from total RNA using M-MLV Reverse Transcriptase according to the manufacturer's instructions (GIBCO). PCR was performed for a total of 35 cycles using an annealing temperature of 618C and the following primers for p14ARF cDNA: (F) 5'-AAGGATCCATGGTGCGCAGGTTCTTGG-3' and (R) 5'-GTTGTGGCGGGGGCAGTTGT-3'. Ten microliters from each reaction was run on 1% agarose gels and transferred onto Hybond N+membranes (Amersham, Buckinghamshire, UK). Membranes were probed with 32 P-dCTP-labeled probes corresponding to exon 1b. Hybridizing bands were visualized using PhosphoImager (Molecular Dynamics). GAPDH cDNA was ampli®ed by RT-PCR using the primers: 5'-TGCCTCCTGCACCACCAACTG-3' (GAPDHE7F) and 5'-ATGCCAGCCCCAGCGTCAAAG-3' (GAPDHE8R) p14ARF and MDM2 alterations in Burkitt lymphoma MS Lindstro Èm et al
First, RT ± PCR revealed that p14ARF mRNA was abundantly expressed in all BL lines that had retained CDKN2A locus but not detected in BL lines carrying homozygous deletion of this locus (results for a subset of BL lines are shown in Figure 1b) . Thus, p14ARF expression is not downregulated by hypermethylation Figure 2 Immun¯uorescence staining analysis of p14ARF, MDM2 and Bmi-1 in BL lines. Bmi-1 was detected in the nucleus of human diploid ®broblasts and in U2OS cells (a ± d, i). Note the close association of Bmi-1 with the nucleolus (i). DG75 and BL41 lines displayed strong accumulation of Bmi-1 in intranuclear dots (e,f,j), whereas Seraphine and majority of other BL lines showed a more homogenous weak nucleoplasmic Bmi-1 staining (g,h, see text for details). p14ARF was detected in majority of Burkitt lymphoma lines, here exempli®ed by Namalwa and BL41 (k ± n). p14ARF was localized to nucleoli, as evidenced by B23 and p14ARF double immunostaining (o ± q) and phase contrast microscopy (r,s). MDM2 protein was easily detected by mAb SMP14 in Seraphine cells where it was localized to discrete nuclear blobs (x). Seraphine only showed weak p53 immunoreactivity with the polyclonal anti-p53 antibody FL393 (t). Scale bars; a ± h, k ± n 10 mM; i,j, o ± s, x 5 mM and t ± v 20 mM. Materials and methods: The MDM2 speci®c mouse monoclonal antibody SMP14 (diluted 1 : 200) and mouse monoclonal anti-p14ARF (14P02) were purchased from Neomarkers/Labvision Corp., Fremont, CA, USA and diluted 1 : 100. Our p14ARF speci®c rabbit polyclonal antiserum 271 (diluted 1 : 100) has been described (LindstroÈ m et al., 2000) . The Bmi-1 F6 mouse monoclonal (diluted 1 : 100) was a kind gift from Maarten van Lohuizen (Netherlands Cancer Institute, Amsterdam, The Netherlands) and has been described (Alkema et al., 1997) . Nucleolus speci®c marker antibody B23/nucleophosmin (1 : 200) was a generous gift from Pui K Chan (Baylor College, TX, USA). Goat-polyclonal antibody FL-393 (1 : 400) against human p53 was obtained from Santa Cruz. Secondary¯uorescent antibody kits were from VECTOR (Vector Laboratories, Inc. Burlingame, CA, USA) and included horse anti-mouse lg antibodies conjugated with FITC, Texas Red and AMCA and also goat anti-rabbit lg (FITC, Texas Red and AMCA). FITC conjugated rabbit anti-goat lg was purchased from Sigma (St Louis, MO, USA). Secondary antibodies were diluted 1 : 50-1 : 100. For immuno¯uorescence studies, smears from exponentially growing suspension cells were prepared on glass slides using a cytospin centrifuge (usually 1500 r.p.m. for 5 min) and then ®xed in 4% paraformaldehyde for 10 min, followed by permeabilization in 0.2% NP40 in PBS for 3 min. Adherent cell lines were seeded onto glass slips in 6-well tissue culture dishes and grown for 24 ± 28 h. Cells at 70 ± 90% con¯uence were ®xed in 4% paraformaldehyde for 10 min and permeabilized in 0.2% NP40 for 5 min. Antibodies and normal sera were diluted in blocking buer (2% BSA, 0.2% Tween-20, 10% glycerol, 0.05% NaN 3 in sterile PBS). For DNA staining, Hoechst dye 33258 was included in the BSA-blocking buer during the last antibody incubation. Procedures for immunostaining, image capturing and analysis have been described (LindstroÈ m et al., 2000) in BL, in contrast to p16INK4a (Klangby et al., 1998; Baur et al., 1999) . Using a p14ARF monoclonal antibody we found that all BL lines harboring mutant p53 expressed low to moderate levels of p14ARF that was localized to nucleoli Figure 2k ± n) as evidenced by phase-contrast microscopy and double immunostaining with an antibody against the nucleolar protein B23/ nucleophosmin (Figure 2o ± s) . p14ARF was not detected by Western blotting (Wb) nor immuno¯uor-escence (IF) staining in our BL lines encoding wt p53, in agreement with the notion that p53 represses the ARF promoter (Robertson and Jones, 1998) . The BL line BL41 had the highest levels of p14ARF (Figures  2k and 3a) . Other lines expressed lower but clearly detectable levels of p14ARF (Table 1) . In summary, our data demonstrate that p14ARF protein is expressed and localized to nucleoli in BL lines carrying mutant p53. Thus, the previously described correlation between mutant p53 status and overexpression of ARF (Quelle et al., 1995; Stott et al., 1998 ) is applicable to BL lines, in keeping with the proposed ARF-p53 feed back loop (Stott et al., 1998) , and suggesting that the presence of nucleolar p14ARF is a good indicator for the p53 gene status in BL lines.
Next, a subset of BL lines carrying wt p53 were examined with regard to bi-allelic deletion of CDKN2A using PCR primers speci®c for exon1b and exon 2. The wild type p53-carrying BL28, Ew36 and BL2 lines all had homozygous deletion of CDKN2A (Table 1, Figure 1a) . On the other hand, Ly47, Ly91, and BL7 that also carry wild type p53 retained at least one wild type CDKN2A allele according to PCR and DNA sequencing (Table 1, Figure 1a) . A re-evaluation of our previous data with focus on p14ARF status showed that all of 19 primary BL biopsies had retained intact CDKN2A and expressed p14ARF mRNA (Klangby et al., 1998) . Of a total of 47 established BL lines only three (6%) had lost p14ARF by homozygous deletion (Klangby et al., 1998 ; this study Table 1 ). In a study from another laboratory, one out of eight primary BL biopsies had a deletion of CDKN2A (Stranks et al., 1995) . Thus, loss of p14ARF by homozygous deletion is infrequent in BL biopsies and cell lines but occurs in a subset of lines that harbor wild type p53. Interestingly, all three wild type p53-carrying BL lines that had homozygous deletion of CDKN2A were EBV-negative, whereas the four BL that carried wild type p53 and had retained CDKN2A were EBV-positive (Table 1) .
Mouse plasmacytomas (MPCs) invariably harbor cmyc translocations similar to those found in BL. Our screening of a panel of primary MPC tumors and derived cell lines indicated infrequent homozygous CDKN2A deletion (LindstroÈ m et al., unpublished results). have shown that the p16INK4a promotor is hypermethylated and p19ARF and mRNA expression retained in majority of MPCs, like in BL. Thus, homozygous CDKN2A deletion appears to be much less frequent in both MPC and BL than in lymphomas arising in Eu-myc transgenic mice where CDKN2A deletion occurs in around 20% of the tumors (Eischen et al., 1999) . However, the ARF-MDM2-p53 pathway appears functional in a majority of MPC cell lines (Zhang et al., 2001) , in contrast to BL lines (this study).
DNA sequencing of p14ARF (exon 1b, exon 2 and the immediate upstream promotor region of p14ARF) in all BL lines carrying an intact CDKN2A locus in this study revealed no point mutations or small deletions that could aect p14ARF (Table 1) . Previously, we had found a point mutation creating a Gly to Val change in p14ARF at codon 114 in the BL line Seraphine. To test the functional signi®cance of this point mutation, Seraphine p14ARF cDNA was cloned into the pEGFP-C1 vector and transfected into MCF-7 cells that carry wild type p53 and express MDM2. The Seraphine p14ARF mutant localized in nucleoli and et al., 1998) . Cells were grown at 378C (5% CO 2 ) in Iscove's modi®ed Dulbecco's medium (IMDM) supplemented with penicillin/streptomycin 100 U/ ml, 2 mM L-glutamine and 15% fetal calf serum (GIBCO, Grand Island, NY, USA). The p53 status of the BL lines (except BL28) has been reported (Farrell et al., 1991; Vousden et al., 1993; Capoulade et al., 1998) . cDNA from BL28 was ampli®ed from total RNA using Advantage RT-PCR kit according to the manufacturer's instructions (Clontech, Palo Alto, CA, USA). p53 was sequenced from pooled PCR reactions using the following set of primers:
p53F1, 5'-GAAGGATCCGAGGAGCCGCAGT-3'; p53F781, 5'CTGAGGTTGGCTCTGACTGTACCACCATCC-3'; p53R789, 5'AACAAGCTTATTACCACTGGAGTCTTC-3'; p53R1179, 5'-AGGGAATTCAGTCTGAGTCAGGC-3' induced p53 and MDM2 as eciently as the wt EGFP-C1-p14ARF fusionprotein, when overexpressed (data not shown). We conclude that the Gly to Val substitution at codon 114 does not signi®cantly aect the function of Seraphine p14ARF. MDM2 is overexpressed in certain tumors carrying wild type p53, for instance sarcomas (Oliner et al., 1992; Cordon-Cardo et al., 1994) and lymphomas/ leukemias (Watanabe et al., 1994) . Overexpression of MDM2 is thought to inactivate wild type p53 through binding to the transcriptional transactivation domain of p53 and by increased nucleo-cytoplasmic shuttling and degradation. A previous study demonstrated that MDM2 is overexpressed in some BL lines that carry wild type p53, probably due to enhanced translation (Capoulade et al., 1998) . We found that Seraphine, BL2, Ly47 and Ly91 expressed readily detectable levels of MDM2 protein as shown by Western blotting and immuno¯uorescence staining (Figures 3b and 2u ± x, data not shown). A few other BL lines, i.e. BL60, Raji and DG75, also expressed MDM2 protein but at signi®cantly lower levels. Most BL lines expressed very low or undetectable amounts of MDM2.
Finally, we asked whether expression of Bmi-1 was altered in any of the BL lines. Bmi-1 belongs to a group of Polycomb gene silencers and collaborates with c-myc in lymphoma development (Haupt et al., 1993; Jacobs et al., 1999b) . The CDKN2A locus is proposed to be a key target of Bmi-1 repression (Jacobs et al., 1999a,b) . Using the Bmi-1 monoclonal antibody F6 (Alkema et al., 1997) we examined Bmi-1 expression in our BL lines and in human primary cells and tumor cell lines. In good agreement with ®ndings by others (Alkema et al., 1997; Voncken et al., 1999) we found an intense nuclear Bmi-1 staining in certain distinct sub-nuclear domains in U20S, HeLa and MCF7 cells in addition to a ®ne grained nuclear staining excluding the nucleolus (Figure 2c ,d,i data not shown). Early passage human diploid foreskin ®bro-blasts displayed a weaker ®ne-grained nuclear staining without the large nuclear domains observed in the tumor cell lines (Figure 2a,b) .
The majority of BL lines expressed low to moderate amounts of nuclear Bmi-1 protein (exempli®ed in Figure 2g ,h). Two BL (BL41 and DG75) displayed an intense`classical' Bmi-1 staining pattern similar to that observed in U2OS cells (Figure 2e,f) . Western blotting showed that a majority of the cell lines expressed equally low levels of Bmi-1 protein without any clear correlation to CDKN2A or p53 status (Figure 3c ). We conclude that Bmi-1 protein is not overexpressed in any of the BL lines. However, we cannot rule out the possibility that Bmi-1 co-operates with c-myc during BL development in vivo.
In conclusion, our data demonstrate that the ARF-MDM2-p53 pathway is frequently inactivated in BL cell lines. In our panel, all but one, BL7, had either p53 mutation, homozygous ARF deletion or overexpressed Figure 3 Western blot analysis of p14ARF, MDM2 and Bmi-1 protein in BL lines. (a) Faint bands representing p14ARF were detected in BL lines BL41, DG75, Ramos and Namalwa. Antibody 14P02 (diluted 1 : 500) did not show reactivity in the p14ARF negative cell line MCF-7 (or in BL2, data not shown). HeLa and SW480 were used as strong positive controls (Stott et al., 1998) . (b) MDM2 is overexpressed in BL2 and Seraphine (in comparison with BL28 and Ew36) but is also detected in other lines such as DG75 using monoclonal antibody 2A10 (1 : 500). Thirty mg of protein lysate was loaded in each well. (c) Bmi-1 protein was detected using the F6 monoclonal (1 : 300) in all BL lines tested. HeLa cells were used as a positive control. Materials and methods: Total cell extracts were prepared in lysis buer (100 mM Tris pH 8.0, 150 mM NaCl, 1% NP40, 1 mM phenylmethylsulfonyl¯uoride). Protein concentration was determined using the Bio-Rad protein assay kit (Bio-Rad Laboratories, Hercules, CA, USA). Samples containing equal amounts of protein (usually 30 mg) were separated on 8% (MDM2), 12% (Bmi-1) and 17.5% (p14ARF) SDS polyacrylamide gels and transferred to nitrocellulose membranes (Amersham). Blocking and incubation with primary and secondary antibodies were performed in 5% milk and 0.1% Tween20 in PBS. Immunodetection using the ECL system was carried out according to manufacturer's instructions (Amersham). Membranes were stripped in 2% SDS, 50 mM DTT and 50 mM Tris-HCl (pH 7.0) for 30 min at 708C. Equal loading was veri®ed when reprobing membranes with a mouse monoclonal antibody against b-actin (1 : 500) (Sigma) MDM2. This is consistent with the notion that ablation of ARF-p53 dependent apoptosis in response to c-myc activation provides a strong selective advantage during BL development and probably is an essential genetic change. Further support of this idea comes from studies of non-Hodgkin lymphomas showing that p53 mutation and CDKN2A deletion are mutually exclusive events (Pinyol et al., 2000) . However, CDKN2A deletion is infrequent in BL biopsies (Klangby et al., 1998; Stranks et al., 1995) and cell lines (this study) compared to other B-cell neoplasms. The reason for the bias for p53 mutation in BL is unclear. It is conceivable that hypermethylation of the p16 promoter, which occurs in a majority of BL biopsies and BL lines, reduces further selection for homozygous deletion of the entire CDKN2A locus. This would favor inactivation of the ARF-p53 pathway by other mechanisms, e.g. p53 mutation. Moreover, the presence of EBV and expression of EBV-encoded proteins may have an impact on the selection pressure for homozygous CDKN2A (p14ARF) deletion versus other mechanisms of inactivation of ARF-p53 dependent apoptosis. Although our series of wild type p53-carrying BL lines is too small to draw ®rm conclusions, it is noteworthy that all BL lines that had deleted both CDKN2A alleles were EBV-negative while the remainder were EBV positive. This raises the possibility that EBV somehow tips the balance towards retention of the CDKN2A locus, perhaps through direct inhibition of p16 and/or p14ARF.
Strikingly, we have observed that BL lines having CDKN2A deletions or p53 mutations grow more rapidly in vitro than those with only MDM2 overexpression or no alteration at all in agreement with observations by others (Gronbaek et al., 2000; Pinyol et al., 2000; Schmitt et al., 1999) . This may be due to incomplete inactivation of p53-dependent apoptosis by MDM2 overexpression. Indeed, some studies have indicated that p53 may still respond to anticancer drugs, such as etoposide, in BL cells that overexpress MDM2 (Gao et al., 1999) .
Our results emphasize the need to examine all components of the ARF-MDM2-p53 pathway in a given tumor in order to assess its p53 function. They also stress the importance of developing therapeutic methods aiming at pharmacological rescue of this pathway in human tumors, either by reintroduction of p14ARF, reactivation of mutant p53, or disruption of the MDM2-p53 protein complex.
